Sun Pharma Brazil Approval, SBI Card-Google Pay Launch, Waaree Solar

Sun Pharmaceutical Industries has secured regulatory approval from the Brazilian Health Regulatory Agency (ANVISA) to manufacture and market semaglutide injection in Brazil. This approval targets adults with inadequately controlled type 2 diabetes mellitus, to be used as an adjunct to diet and exercise.

Sun Pharma plans to launch the product in the next few days in partnership with Hypera Pharma, a prominent pharmaceutical company in Brazil.

Brazilian Market Expansion

The semaglutide injection will be available as a pre-filled, multi-dose injectable pen, designed for flexible, once-weekly dosing.

• Approved Strengths: 2 mg/1.5 mL and 4 mg/3 mL

New Co-Branded Card Launch

Separately, SBI Cards and Payment Services, in collaboration with Google Pay, has introduced the ‘Google Pay Flex SBI Card’. This co-branded offering is specifically designed to simplify and elevate the everyday payment experience for consumers.

The card delivers a convenient blend of rewards, flexibility, and security, effectively bringing together SBI Cards’ trusted credit card expertise with Google Pay’s extensive digital ecosystem.

Waaree Energies Commissions Solar Capacity

In the renewable energy sector, Waaree Energies has successfully commissioned a significant portion of its solar power facility located at Neemuch Solar Park in Madhya Pradesh.

This commissioning event, which occurred on July 28, 2026, represents a crucial step in expanding the company’s operational solar generation capabilities within the region.

• Capacity Commissioned: 118.8 MW (out of a total 170 MW for Unit 3)
• Location: Neemuch Solar Park, Madhya Pradesh
• Commissioning Date: July 28, 2026

These developments highlight strategic advancements across India’s pharmaceutical, financial, and renewable energy sectors.